Jove
Visualize
Contact Us

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

525
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
525
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

622
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
622
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

566
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
566
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

832
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
832
Glaucoma: Overview01:25

Glaucoma: Overview

696
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
696

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclodextrin-Based Niosomal Delivery of Imatinib against A549 Nonsmall Cell Lung Cancer Cells.

ACS omega·2026
Same author

Cyclodextrin-based formulations for pediatric patients: pharmaceutical prospectives and toxicological evaluation.

The Journal of pharmacy and pharmacology·2025
Same author

The Chemical Stability Characterization and Kinetics of Statins in Aqueous Cyclodextrin Ocular Preparations: A Formulation Perspective.

Pharmaceutics·2025
Same author

Antimicrobial Preservatives in Cyclodextrin-Containing Drug Formulations.

Pharmaceutics·2025
Same author

New Improved cGMP Analogues to Target Rod Photoreceptor Degeneration.

Journal of medicinal chemistry·2024
Same author

Celecoxib/Cyclodextrin Eye Drop Microsuspensions: Evaluation of In Vitro Cytotoxicity and Anti-VEGF Efficacy for Retinal Diseases.

Pharmaceutics·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 23, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.3K

Aqueous Prostaglandin Eye Drop Formulations.

Phatsawee Jansook1, Thorsteinn Loftsson2

  • 1Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phyathai Road, Pathumwan, Bangkok 10330, Thailand.

Pharmaceutics
|October 27, 2022
PubMed
Summary

Prostaglandin analogues (PGAs) are key for treating glaucoma by lowering eye pressure. New formulations aim to improve PGA stability and reduce side effects for better bioavailability and efficacy.

Keywords:
aqueous solubilitychemical stabilitydrug deliveryintraocular pressureocular hypertensionprostaglandin analogues

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.7K
Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
06:29

Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation

Published on: May 2, 2020

3.9K

Related Experiment Videos

Last Updated: Aug 23, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.3K
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.7K
Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
06:29

Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation

Published on: May 2, 2020

3.9K

Area of Science:

  • Ophthalmology
  • Pharmaceutics
  • Medicinal Chemistry

Background:

  • Glaucoma is a leading cause of irreversible blindness globally, characterized by optic nerve damage and vision loss.
  • Prostaglandin analogues (PGAs) are first-line treatments for open-angle glaucoma, reducing intraocular pressure (IOP) via enhanced fluid outflow.
  • Conventional PGA eye drops face challenges due to low aqueous solubility, instability, and ocular side effects like hyperemia.

Purpose of the Study:

  • To review the physiochemical properties and chemical stabilities of commercially available prostaglandin analogues (PGAs).
  • To discuss the compositions of current PGA eye drop formulations.
  • To explore novel PGA formulations for improved glaucoma treatment.

Main Methods:

  • Literature review of physiochemical properties of PGAs.
  • Analysis of chemical stability data for marketed PGA formulations.
  • Review of scientific literature on novel PGA delivery systems.

Main Results:

  • PGAs exhibit low aqueous solubility and are prone to hydrolysis, impacting bioavailability and stability.
  • Existing PGA formulations present challenges in achieving optimal therapeutic efficacy and minimizing ocular side effects.
  • Emerging formulations aim to enhance solubility, stability, and ocular delivery of PGAs.

Conclusions:

  • Stable and effective PGA eye drop formulations are crucial for managing glaucoma and preventing blindness.
  • Overcoming the inherent instability and low solubility of PGAs is essential for improving patient outcomes.
  • Novel formulation strategies hold promise for enhancing the therapeutic performance of PGAs in glaucoma treatment.